Abstract
A plaque-reduction assay for the determination of neutralizing antibody to human coronavirus OC43 has been set up, using as a plaquing factor the fetal calf serum containing an OC43 inhibitor. A similar inhibitor has also been found in human sera both negative and positive for OC43 antibody. The inhibitor can be removed by treatment of sera with phospholipase C and is likely to be a lipoprotein of the high density class. The new plaque-reduction assay appears to be a very sensitive test for both OC43 antibody determination and serodiagnosis of OC43 infections. It may also be very useful for studies of antigenic relationships between human and animal coronaviruses. However, before testing, sera must be routinely treated for removal of viral inhibitor.
| Original language | English |
|---|---|
| Pages (from-to) | 360-366 |
| Number of pages | 7 |
| Journal | Proceedings of the Society for Experimental Biology and Medicine |
| Volume | 163 |
| Issue number | 3 |
| Publication status | Published - 1980 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Human coronavirus OC43 serum inhibitor and neutralizing antibody by a new plaque-reduction assay. / Gerna, G.; Cattaneo, E.; Cereda, P. M.; Revelo, M. G.; Achilli, G.
In: Proceedings of the Society for Experimental Biology and Medicine, Vol. 163, No. 3, 1980, p. 360-366.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Human coronavirus OC43 serum inhibitor and neutralizing antibody by a new plaque-reduction assay
AU - Gerna, G.
AU - Cattaneo, E.
AU - Cereda, P. M.
AU - Revelo, M. G.
AU - Achilli, G.
PY - 1980
Y1 - 1980
N2 - A plaque-reduction assay for the determination of neutralizing antibody to human coronavirus OC43 has been set up, using as a plaquing factor the fetal calf serum containing an OC43 inhibitor. A similar inhibitor has also been found in human sera both negative and positive for OC43 antibody. The inhibitor can be removed by treatment of sera with phospholipase C and is likely to be a lipoprotein of the high density class. The new plaque-reduction assay appears to be a very sensitive test for both OC43 antibody determination and serodiagnosis of OC43 infections. It may also be very useful for studies of antigenic relationships between human and animal coronaviruses. However, before testing, sera must be routinely treated for removal of viral inhibitor.
AB - A plaque-reduction assay for the determination of neutralizing antibody to human coronavirus OC43 has been set up, using as a plaquing factor the fetal calf serum containing an OC43 inhibitor. A similar inhibitor has also been found in human sera both negative and positive for OC43 antibody. The inhibitor can be removed by treatment of sera with phospholipase C and is likely to be a lipoprotein of the high density class. The new plaque-reduction assay appears to be a very sensitive test for both OC43 antibody determination and serodiagnosis of OC43 infections. It may also be very useful for studies of antigenic relationships between human and animal coronaviruses. However, before testing, sera must be routinely treated for removal of viral inhibitor.
UR - http://www.scopus.com/inward/record.url?scp=0018827886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018827886&partnerID=8YFLogxK
M3 - Article
C2 - 6244598
AN - SCOPUS:0018827886
VL - 163
SP - 360
EP - 366
JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)
JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)
SN - 0037-9727
IS - 3
ER -